A sales partner offered a ray of hope that this company couldn't for itself.

CRISPR Therapeutics (NASDAQ:CRSP) is one of the best emerging technology stocks to invest in. On December 22, CRISPR Therapeutics released a comprehensive clinical update on zugocaptagene geleucel ...

2026 could be a big year for this company.

CRISPR Therapeutics reached a significant milestone a couple of years ago: its first product approval. The company’s stock, once a highflier, has declined from its peak. CRISPR Therapeutics (NASDAQ: ...

Sales of Casgevy, a gene-edited treatment developed with CRISPR Therapeutics, more than tripled compared to the third quarter, a performance analysts saw as a bright spot in Vertex's report.

ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial ...

In the latest close session, CRISPR Therapeutics AG (CRSP) was down 8.7% at $55.52. The stock fell short of the S&P 500, which registered a gain of 0.03% for the day. On the other hand, the Dow ...

On December 24, Kevin Simpson of Capital Wealth Planning joined ‘Closing Bell’ on CNBC to talk about AI tailwinds and the diverging tech picture. Given the current market dynamics, Simpson confirmed ...

CRISPR Therapeutics reached a significant milestone a couple of years ago: its first product approval. The company’s stock, once a highflier, has declined from its peak. First, let's talk a bit about ...